{
  "eval_id": "S31",
  "score": 100,
  "pass": true,
  "findings": [
    "Response accurately states Trodelvy's on-label indication for ER-positive, HER2-negative metastatic breast cancer after prior endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor.",
    "References the TROPiCS-02 trial and directs to the EMA SmPC/EPAR for further details, which is appropriate and compliant.",
    "No off-label suggestions or promotional language present."
  ],
  "rationale": "The response is strictly on-label, clinically relevant, and avoids any off-label or promotional content. It provides clear, succinct information and appropriately refers to regulatory documents for further detail.",
  "timestamp": "2025-09-18T17:17:21.420088+00:00",
  "model": "gpt-4.1"
}